GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Agenus Inc. (AGEN) [hlAlert]

Rating:
Mkt Outperform
AGEN
up 620.54 %

Agenus Inc. (AGEN) rated Mkt Outperform with price target $2 by Rodman & Renshaw

Posted on: Monday,  May 9, 2011  3:25 PM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Agenus Inc. (NASDAQ: AGEN) on 05/09/2011, when the stock price was $0.96.
Since then, Agenus Inc. has gained 620.54% as of 01/21/2016's recent price of $6.91.
If you would have followed this Rodman & Renshaw's recommendation on AGEN, you would have gained 620.54% of your investment in 1718 days.

Antigenics Inc. is engaged in the discovery and development of a family of novel immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight disease. The company is evaluating the lead immunotherapeutic, Oncophage, in six separate phase II or phase I/II clinical trials in four different cancers. The company is also developing immunotherapeutics to treat infectious diseases, such as genital herpes, and autoimmune disorders, such as diabetes and multiple sclerosis.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/9/2011 3:25 PM Buy
None
0.96 2.00
as of 12/30/2011
1 Week down  -9.50 %
1 Month down  -17.35 %
3 Months up  325.53 %
1 YTD up  108.55 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy